The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.
Suzanne Fields Jones
No relevant relationships to disclose
Carla Kurkjian
No relevant relationships to disclose
Manish R. Patel
No relevant relationships to disclose
Jeffrey R. Infante
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
F Anthony Greco
No relevant relationships to disclose
Michael Brian Hemphill
Honoraria - Bayer; Eisai; Novartis
Adil I. Mohyuddin
No relevant relationships to disclose
Dana Shelton Thompson
No relevant relationships to disclose
Patrick Murphy
No relevant relationships to disclose
Eric Raefsky
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose